Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-01-18

FDA Approved: RHOFADE — Original Application (EPI Health, LLC)

View source ↗

Summary

FDA approves Rhofade (oxymetazoline hydrochloride) from EPI Health as an original application for the treatment of persistent facial redness associated with ros…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RHOFADE (oxymetazoline hydrochloride)

Snippet

ORIG AP for RHOFADE (OXYMETAZOLINE HYDROCHLORIDE)